These investigations suggest that the HER2-derived vaccines possess a promising prospect of research in breast cancer treatment, especially when combined with adjuvant or HER2 monoclonal antibody and kinase inhibitor, for the mild toxicity and well clinical responses. The gene discussed is ERBB2; the disease is breast cancer.